

Greater Manchester Medicines Management Group

Minutes of the meeting held on
Thursday 9th March 2023, 1-3pm

Virtual meeting

Name	Title	Organisation	Representing	Jul	Aug	Sep	Oct	Nov	Dec	Feb	Mar
Dr Helen Burgess (HB)	GP MO Prescribing lead	GM ICB - Manchester	GPs	✓		✓	✓	✓	✓	✓	✓
Petra Brown (PeB)	Chief Pharmacist	Pennine care NHS FT	GM Mental Health Organisations	A	✓	✓	✓	✓	✓	A	✓
Kate Rigden (KR)	Chief Finance Officer	GM ICB	ICB finance	✓	A	✓	✓	✓	A	✓	✓
Mina Patel (MP)	Trust Finance Officer	MFT	Provider Finance	✓	✓	✓	✓	✓	✓	✓	✓
Jay Hamilton (TBC)		HiM	Health Innovation Manchester (HiM)	A	A	A	A	A	✓	A	A
Dr Ann Harrison (AH)	GP MO Prescribing lead	GM ICB - Trafford	GPs	✓	✓	✓	✓	✓	✓	A	✓
Robert Hallworth (RH)	Specialist Cancer Pharmacist	NHSE	NHSE Specialised Commissioning	✓	✓	A	✓	A	✓	✓	✓
Dr Pete Budden	GP Prescribing lead	GM ICB - Salford	GMMMG Clinical Referen	✓	✓	✓	A	✓	✓	✓	✓

			ce Subgroup									
Aneet Kapoor	Chair of the GM LPN	LPN	Pharmacy profession	✓	A	✓	✓	✓	✓	✓	✓	✓
Vacant seat			GM Secondary Care Clinicians									
Peter Marks (PM)	LPC Board Member	GM LPC	Community Pharmacy	✓	✓	✓	✓	✓	✓	✓	✓	✓
Chris Haigh (CH)	HOMM	GM ICB - Bolton	CCG MO leads and GMMMG Digital subgroup	✓	✓	✓	✓	✓	✓	✓	✓	A
Luvjit Kandula (LK)	Chair – Community Pharmacy Provider Board (CPPB)	GM LPC	Community Pharmacy	A	✓	✓	✓	✓	✓	✓	✓	✓
Lara Shah (LS)	Deputy HOMM	GM ICB - Manchester	GMMMG Population health and inequalities subgroup	✓	✓	✓	✓	✓	✓	A	A	
Fiona Meadowcroft (FC)	Interim Deputy Director Strategy – Integrated Care	GM ICB – commissioning (TBC)	CCG Commissioning lead	A	✓	A	A	A	✓	✓	✓	✓
Kenny Li	GM Chief Pharmacist	GM ICB	GMMMG Medicines Value subgroup	A	✓	✓	✓	✓	✓	✓	✓	✓

Faisal Bokhari or Heather Bury	HOMM	GM ICB – T&G NHS GM ICB	GMMMG Pharmacy workforce subgroup	✓	✓ HB	HB	✓ HB	✓	✓ HB	✓ FB	✓ FB
Karen O'Brien (KO'B)	Regional Pharmacist	NHSEI	NHSEI	A	A	✓	A	✓	✓	✓	✓
Paul Buckley (PaB)	Chief Pharmacist	Stockport FT	GM Chief pharmacists	✓	✓	✓	✓	✓	✓	✓	✓
Steve Simpson (SS)	Chief Pharmacist	Bolton FT	GM Chief pharmacists	A	✓	✓	✓	✓	✓	✓	✓
Charlotte Skitterall (CS)	Chief Pharmacist	Manchester FT	Chair	✓	✓	A	✓	✓	✓	✓	✓
Claire Vaughan (CV)	Head of MO	GM ICB - Salford	Vice Chair of GMMMG and GMMMG Medicines Safety subgroup	✓	A	✓	✓	✓	✓	✓	✓
Dr Sanjay Wahie (SW)	Clinical Director	GM ICB - Wigan	GPs	A	✓	✓	✓	✓	✓	✓	✓
Dr Peter Elton	SCN representatives	Strategic Clinical Network	Strategic Clinical Network	✓	✓	✓	✓	✓	✓	A	✓
Vacant seat			Provider Board representative								
Vacant seat			Council representative for GM Social Services								
Vacant seat			GM Medical								

			Director s								
Vacant seat			Lay repre senta tive								
Vacant seat			GM Public Health								
Monica Mason (MM)	Head of Prescribin g Support	RDTC	Professi onal secretar y	A	✓	✓	✓	✓	✓	✓	✓
Andrew Martin (AM)	MO Pharmacis t	GM Joint Commissio ning team	GMMM G support	A	A	A	✓	✓	✓	✓	✓
Dan Newsome (DN)	Principal pharmacis t	RDTC	GMMM G support	✓	✓	✓	A	✓	✓	✓	✓

1. General Business

1.1 Apologies

As above. MP had to leave the meeting at 1-2pm.

Declarations of Interest

Nil raised

2.0 Minutes and actions from the last meeting

Minutes from the February meeting were approved for publication. The group considered the outstanding actions as follows:

- Ophthalmology pathway is now drafted with input from acute and private providers. It includes the use of the biosimilar first but some providers are challenging this as there are products available now which may deliver better value and require less administration frequency. GMMM awaits submission of this pathway for its consideration
- CGM - The GMMM recommendation to provide access to CGM in line with NICE guidance awaits approval from executive, who have requested further financial impact information be provided.
- Delegation of spec comm/HCD group – it was understood that the state of readiness reports are not yet available
- Obesity treatments funding bid – JH was not available for this meeting, CS will return further information once available
- Primary care winter surge plans and CP – closed, remove from action log
- SCPs – GMMM understood some meetings had been held to discuss commissioning of mental health SCPs. KL to contact PBr to discuss attending future meetings
- Early value assessment: Genedrive MT RNR1 ID Kit for detecting a genetic variant to guide antibiotic use and prevent hearing loss in babies - SS, PBU to ensure this item is discussed at the next available Trust CP meeting

- Medicines value ToR now expected in April, after which KL will have met with Trust CPs and discussed the system wide medicines value plan also. GMMMG members raised concern that we didn't seem to making progress with a system wide approach to medicines value. KL, KR and MP explained that complexity of producing the necessary reports to capture system wide financial impacts of prescribing. KO'B highlighted the national medicines optimization priorities which were being developed by the NHSE medicines policy team, GMMMG members also highlighted system wide initiatives regarding medicine waste, with an example of a decline in the use of patients own medicines in secondary care setting since the start of the pandemic. PM highlighted a campaign running in Stockport to support patient ordering of medicines, which might be able to support this issue.

GMMMG again asked for strategic direction with regards its priorities for 2023/24, which should support a system wide approach, which should be GM wide and truly cross-sector. KL responded that these objectives need to be developed in line with the ICB objectives, and by a group. GMMMG will revisit its charter and the high-level objectives contained within when directed.

3.0 Medicines decisions for ratification (Feb)

GMMMG approved all the recommendations presented for submission to CEGC March meeting. The GM adoption of national shared care protocols was retracted from the agenda pending confirmation from NHSE on a number of queries.

Action: RDTC to publish decisions upon receipt of CEGC approval and where necessary executive approval.

4.0 Rebate for Ranexa (Ranolazine)

GMMMG understood that these savings do not meet the rebate ethical framework threshold of £50,000 savings across GM, and supported the proposal that this rebate is rejected on this basis.

5.0 ICB statutory responsibility: NICE guidance

GMMMG demonstrates NICE compliance through the updating of its formulary and guidance through the GMMMG website. It attempts to gather agreement to proposed decisions from across the system, through a 6-week open consultation process.

The GMMMG recommendations from the February 2023 meeting that posed a financial impact were awaiting approval by the ICB executive, pending further financial impact information. ICB finance leads have been asked to work with pharmacy and medicines leads to further detail the financial impact and returns expected from these recommendations.

GMMMG was asked to highlight to the executive the statutory obligations around NICE appraisals and guidance, and these were presented in a paper which included the following recommendations:

1. GMMMG recommend to the GM executive that they accept any statutory recommendation issued by NICE, utilising the NICE costing impact presented, as close to the 90-day (or 30 day) schedule as possible.
2. GMMMG will highlight to the GM executive the impact of not adopting NICE guidance and recommend to the GM executive that they provide treatment access as detailed within NICE guidance. ICB finance colleagues will work with pharmacy and medicines leads to provide the necessary financial information to executive.

GMMMG expressed thoughts on the need for this paper, and the frustrations that clinicians in particular were feeling, with regard the repeated ask for further financial impacts of decisions. However, GMMMG approved this paper and its recommendations for submission to CEGC and then on to executive but asked KL to add these delays in medicines decision making to the ICB risk register.

Action: MM to submit to CEGC

6.0 Pharmacy workforce subgroup: progress paper

FB presented a paper providing an overview of the national background for pharmacy professional practice, update on the Greater Manchester (GM) Integrating Pharmacy and Medicines Optimisation (IPMO) Workforce group setting out next steps for the development of the NHS Greater Manchester Pharmacy Workforce Strategy.

The paper highlighted governance related considerations for the GM IPMO Workforce group.

This paper was well received by GMMMG who said it was an excellent piece of work, picking up many of the current issues. Members asked if consideration could be given to “early years” groups particularly, and suggestions were made for undergraduate placements. Additionally the need to focus on technical services was raised i.e. aseptic services where workforce would be key.

In response to the question raised, FB confirmed that this is intended as a GM strategy and would relate local workforce strategies.

GMMMG confirmed its support for submission of this paper to CEGC, and for further consultation as necessary.

Action: MM to submit to CEGC

7.0 Optimising personalised care for adults prescribed medicines associated with dependence and withdrawal symptoms: Framework for Action for ICBs and Primary Care

Petra B introduced this framework to the group where it was welcomed. It was agreed that a gap analysis be undertaken to see where GM sits currently against this framework. The medicines safety subgroup agreed to accept this piece of work in.

Action: CV to table at medicines safety subgroup

AOB

- The group noted the changes to the GP contract in 2023/24 and that the GMMMG priorities and charter may need to be realigned accordingly.
- The group noted that the “Regional arrangements for Medicines Optimisation in the NHS in England - Framework for Integrated Care Boards, and Regional Medical Directors, Pharmacists and Chief Nursing Officers” currently in draft would be shared with GMMMG upon publication

Date of next meeting: Thursday 13th April 2023, 1 – 3pm